Growth hormone effects on insulin cells in adults with diabetes family history
Studies how growth hormone affects insulin-making pancreas cells in adults with family history.
Plain-language title generated from the registry record
Registry title: Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes
Key facts
- Where
- Columbia, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 59 years old?
Source: NCT06571500, who can take part
Where in United States
- University of Missouri School of MedicineColumbia, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Missouri-Columbia
- Trial code
- NCT06571500
- Record updated
- 11 May 2026
- Original description
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.Read full original descriptionShow less
Growth Hormone Resistance of Beta-cells in People With a Family History of Type 2 Diabetes
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a family history of type 2 diabetes at the University of Missouri. Our aim is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.
Inclusion: 18 to 59 years old; body mass index ≥30.0 kg/m2 and <45.0 kg/m2; Additional, group-specific inclusion criteria:; Family history of type 2 diabetes: first degree relative with type 2 diabetes; Control group: no family history of type 2 diabetes.
Exclusion: Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists); Current diagnosis or history of type 1 or type 2 diabetes; History of bariatric surgery; History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment; Current cancer or cancer that has been in remission less than 5 years; First degree relative with type 1 diabetes diagnosis; Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease); Alcohol use disorder, use of controlled substances, or smoking >2 cigarettes per day; Pregnant, planning to become pregnant during the study, or breastfeeding; Known, uncontrolled hypothyroidism; Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration; Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent.